公开(公告)号：EP3589283A1

公开(公告)日：2020-01-08

申请号：EP18760726.2

申请日：2018-02-27

Applicant: India Globalization Capital, Inc.

Inventor： MUKUNDA, Ramachandra

IPC: A61K31/352 ,  A61P1/14

公开(公告)号：EP4182026A1

公开(公告)日：2023-05-24

申请号：EP21843338.1

申请日：2021-07-19

Applicant: India Globalization Capital, Inc.

Inventor： MUKUNDA, Ramachandra ,  RAO, Jagadeesh Sridhara

IPC: A61P29/00 ,  A61K31/352 ,  A61K36/886 ,  A61K36/534 ,  A61K36/67 ,  A61K31/4172

公开(公告)号：EP3972573A1

公开(公告)日：2022-03-30

申请号：EP20809522.4

申请日：2020-05-26

Applicant: India Globalization Capital, Inc.

Inventor： MUKUNDA, Ramachandra ,  RAO, Jagadeesh, S. ,  MUKUNDA, Amar, R.

IPC: A61K31/01 ,  A61K31/015 ,  A61K31/045

公开(公告)号：EP3193862A1

公开(公告)日：2017-07-26

申请号：EP15841994.5

申请日：2015-09-16

Applicant: India Globalization Capital Inc.

Inventor： MUKUNDA, Ramachandra ,  KRISHNA, Ranga Chelva

IPC: A61K31/352

CPC classification number: A61K31/714 ,  A61K9/0014 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K47/44 ,  A61K2300/00

Abstract: A combination of THC, CBD and Cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as Shea butter cream to relieve pain. The THC and CBD mixture is extracted from a Cannabis Indica dominant strain using high pressure and carbon dioxide (CO2) as a solvent and comprises: Tetrahydrocannabinol “THC” (9-Tetrahydrocannabinol (delta-9 THC), 8-Tetrahydrocannabinol (Delta-8 THC) and 9-THC Acid), Cannabidiol “CBD”, Cannabinol “CBN”, Cannabichromene (“CBC”), Cannabigerol (“CBG”), terpenoids and flavonoids. The Shea butter is an extract from the Shea nut from the Shea tree (Vitellaria paradoxa).

Abstract translation: THC，CBD和钴胺素（分别为约63％，27％和10％的比例）的组合与局部载体如牛油树脂奶油一起使用以缓解疼痛。 使用高压和二氧化碳（CO 2）作为溶剂从大麻印度优势菌株提取THC和CBD混合物，并包含：四氢大麻酚“THC”（9-四氢大麻酚（δ-9THC），8-四氢大麻酚（δ-8 大麻酚“CBN”，Cannabichromene（“CBC”），Cannabigerol（“CBG”），萜类化合物和类黄酮。 牛油树脂是从牛油树（维拉里亚paradoxa）的牛油树坚果的提取物。

公开(公告)号：EP3773527A1

公开(公告)日：2021-02-17

申请号：EP19777467.2

申请日：2019-03-29

Applicant: India Globalization Capital, Inc.

Inventor： MUKUNDA, Ramachandra ,  RAO, Jagadeesh S. ,  MUKUNDA, Amar R.

IPC: A61K31/05 ,  A61K31/137 ,  A61K31/4045

公开(公告)号：EP3471746A1

公开(公告)日：2019-04-24

申请号：EP17813993.7

申请日：2017-06-14

Applicant: India Globalization Capital, Inc.

Inventor： MUKUNDA, Ramachandra ,  KRISHNA, Ranga, Chelva

IPC: A61K36/185 ,  A61K31/05 ,  A61K31/202 ,  A61K31/4015 ,  A61K45/06

公开(公告)号：EP3193862A4

公开(公告)日：2018-05-16

申请号：EP15841994

申请日：2015-09-16

Applicant: INDIA GLOBALIZATION CAPITAL INC

Inventor： MUKUNDA RAMACHANDRA ,  KRISHNA RANGA CHELVA

IPC: A61K31/352 ,  A61K31/714 ,  A61P25/00 ,  A61P25/02

CPC classification number: A61K31/714 ,  A61K9/0014 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K47/44 ,  A61K2300/00

Abstract: A combination of THC, CBD and Cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as Shea butter cream to relieve pain. The THC and CBD mixture is extracted from a Cannabis Indica dominant strain using high pressure and carbon dioxide (CO2) as a solvent and comprises: Tetrahydrocannabinol “THC” (9-Tetrahydrocannabinol (delta-9 THC), 8-Tetrahydrocannabinol (Delta-8 THC) and 9-THC Acid), Cannabidiol “CBD”, Cannabinol “CBN”, Cannabichromene (“CBC”), Cannabigerol (“CBG”), terpenoids and flavonoids. The Shea butter is an extract from the Shea nut from the Shea tree (Vitellaria paradoxa).

公开(公告)号：EP3247359A1

公开(公告)日：2017-11-29

申请号：EP16740521.6

申请日：2016-01-14

Applicant: India Globalization Capital, Inc.

Inventor： MUKUNDA, Ramachandra ,  KRISHNA, Ranga Chelva

IPC: A61K31/515

CPC classification number: A61K31/07 ,  A61K31/05 ,  A61K31/513 ,  A61K31/515 ,  A61K36/185 ,  A61K45/06 ,  A61K2300/00 ,  A61P25/08

Abstract: The invention provides compositions and methods for treating seizure disorders such as epilepsy in humans and animals using, in a first embodiment, the combination of (i) an effective amount of a barbiturate drug, such as phenobarbital or primidone, which solely enhances GABAergic inhibition in a patient suffering a seizure disorder; and (ii) phytocannabinoid cannabidiol (CBD) in a dosage amount sufficient to overcome the hepatic metabolic effect stimulated by the barbiturate drug and provide bioavailable CBD to the patient in clinically efficacious amounts.